.png){kind=icon}
.png){kind=icon}
Return
Safety Evaluation of Glutaric Acid as a Novel Pharmaceutical Salt for First-In-Human Dosing
.png){kind=icon}
PRE
AI
K
A
DOI：10.1093/toxsci/kfag059.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
Salt selection is critical in pharmaceutical development. Glutaric acid, an endogenous dicarboxylic acid, offers potential advantages as a counterion but is underexplored in pharmaceutical applications. The nonclinical safety of glutaric acid as a pharmaceutical counterion was assessed using LY3972406 hemi-glutarate hemi-hydrate (HG) as a model, with direct comparison to the LY3972406-hydrochloride (HCl) salt.
Keywords:
Glutaric acid
Pharmaceutical salt
Nonclinical safety
LY3972406
Counterion
Journal
IF:
4.1
Papers:
7.2K
Citations:
1.6W
Organization
Cited Papers